Justin B. Klee - 15 Jan 2026 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Co-Chief Executive Officer, Director
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Issuer symbol
AMLX
Transactions as of
15 Jan 2026
Net transactions value
-$363,570
Form type
4
Filing time
20 Jan 2026, 21:46:02 UTC
Previous filing
08 Jan 2026
Next filing
04 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Klee Justin B. Co-Chief Executive Officer, Director C/O AMYLYX PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE /s/ Joshua B. Cohen, as Attorney in Fact 20 Jan 2026 0001898314

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Options Exercise $1,492,448 +197,153 +5.9% $7.57 3,514,739 15 Jan 2026 Direct
transaction AMLX Common Stock Sale $1,849,869 -136,193 -3.9% $13.58 3,378,546 15 Jan 2026 Direct F1, F2
transaction AMLX Common Stock Options Exercise $21,552 +2,847 +0.08% $7.57 3,381,393 16 Jan 2026 Direct
transaction AMLX Common Stock Sale $27,701 -1,995 -0.06% $13.89 3,379,398 16 Jan 2026 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (Right to Buy) Options Exercise $0 -197,153 -99% $0.000000 2,847 15 Jan 2026 Common Stock 197,153 $7.57 Direct F4
transaction AMLX Stock Option (Right to Buy) Options Exercise $0 -2,847 -100% $0.000000 0 16 Jan 2026 Common Stock 2,847 $7.57 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects shares sold to cover option cost and tax obligations upon the option exercise pursuant to a preset sales plan adopted by the reporting person on November 12, 2025.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.83 to $13.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 This option is fully vested and exercisable. The option is due to expire on February 19, 2026.